177 related articles for article (PubMed ID: 38288874)
1. Induced-pluripotent stem cells and neuroproteomics as tools for studying neurodegeneration.
Brandão-Teles C; Zuccoli GS; de Moraes Vrechi TA; Ramos-da-Silva L; Santos AVS; Crunfli F; Martins-de-Souza D
Biochem Soc Trans; 2024 Feb; 52(1):163-176. PubMed ID: 38288874
[TBL] [Abstract][Full Text] [Related]
2. Patient-Specific iPSCs-Based Models of Neurodegenerative Diseases: Focus on Aberrant Calcium Signaling.
Grekhnev DA; Kaznacheyeva EV; Vigont VA
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054808
[TBL] [Abstract][Full Text] [Related]
3. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
Liu Y; Deng W
Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
[TBL] [Abstract][Full Text] [Related]
4. Using induced pluripotent stem cell neuronal models to study neurodegenerative diseases.
Zhang X; Hu D; Shang Y; Qi X
Biochim Biophys Acta Mol Basis Dis; 2020 Apr; 1866(4):165431. PubMed ID: 30898538
[TBL] [Abstract][Full Text] [Related]
5. Induced pluripotent stem cell-based modeling of neurodegenerative diseases: a focus on autophagy.
Jungverdorben J; Till A; Brüstle O
J Mol Med (Berl); 2017 Jul; 95(7):705-718. PubMed ID: 28593578
[TBL] [Abstract][Full Text] [Related]
6. Aging in a Dish: iPSC-Derived and Directly Induced Neurons for Studying Brain Aging and Age-Related Neurodegenerative Diseases.
Mertens J; Reid D; Lau S; Kim Y; Gage FH
Annu Rev Genet; 2018 Nov; 52():271-293. PubMed ID: 30208291
[TBL] [Abstract][Full Text] [Related]
7. Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-cell-based disease models.
Taoufik E; Kouroupi G; Zygogianni O; Matsas R
Open Biol; 2018 Sep; 8(9):. PubMed ID: 30185603
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial resetting and metabolic reprogramming in induced pluripotent stem cells and mitochondrial disease modeling.
Hsu YC; Chen CT; Wei YH
Biochim Biophys Acta; 2016 Apr; 1860(4):686-93. PubMed ID: 26779594
[TBL] [Abstract][Full Text] [Related]
9. New lessons learned from disease modeling with induced pluripotent stem cells.
Onder TT; Daley GQ
Curr Opin Genet Dev; 2012 Oct; 22(5):500-8. PubMed ID: 22749051
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic potential of cell identity reprogramming for the treatment of aging-related neurodegenerative disorders.
Smith DK; He M; Zhang CL; Zheng JC
Prog Neurobiol; 2017 Oct; 157():212-229. PubMed ID: 26844759
[TBL] [Abstract][Full Text] [Related]
11. Human Induced Pluripotent Stem Cell Models of Neurodegenerative Disorders for Studying the Biomedical Implications of Autophagy.
Seranova E; Palhegyi AM; Verma S; Dimova S; Lasry R; Naama M; Sun C; Barrett T; Rosenstock TR; Kumar D; Cohen MA; Buganim Y; Sarkar S
J Mol Biol; 2020 Apr; 432(8):2754-2798. PubMed ID: 32044344
[TBL] [Abstract][Full Text] [Related]
12. Modeling Polyglutamine Expansion Diseases with Induced Pluripotent Stem Cells.
Naphade S; Tshilenge KT; Ellerby LM
Neurotherapeutics; 2019 Oct; 16(4):979-998. PubMed ID: 31792895
[TBL] [Abstract][Full Text] [Related]
13. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells.
Burkhardt MF; Martinez FJ; Wright S; Ramos C; Volfson D; Mason M; Garnes J; Dang V; Lievers J; Shoukat-Mumtaz U; Martinez R; Gai H; Blake R; Vaisberg E; Grskovic M; Johnson C; Irion S; Bright J; Cooper B; Nguyen L; Griswold-Prenner I; Javaherian A
Mol Cell Neurosci; 2013 Sep; 56():355-64. PubMed ID: 23891805
[TBL] [Abstract][Full Text] [Related]
14. Advances in the application of induced pluripotent stem cells in pediatric diseases.
Tian ZC; Yin XJ
Yi Chuan; 2023 Jan; 45(1):42-51. PubMed ID: 36927637
[TBL] [Abstract][Full Text] [Related]
15. Seeing Neurodegeneration in a New Light Using Genetically Encoded Fluorescent Biosensors and iPSCs.
Stellon D; Talbot J; Hewitt AW; King AE; Cook AL
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675282
[TBL] [Abstract][Full Text] [Related]
16. Modeling neurodegenerative diseases with patient-derived induced pluripotent cells: Possibilities and challenges.
Poon A; Zhang Y; Chandrasekaran A; Phanthong P; Schmid B; Nielsen TT; Freude KK
N Biotechnol; 2017 Oct; 39(Pt B):190-198. PubMed ID: 28579476
[TBL] [Abstract][Full Text] [Related]
17. A novel model of urinary tract differentiation, tissue regeneration, and disease: reprogramming human prostate and bladder cells into induced pluripotent stem cells.
Moad M; Pal D; Hepburn AC; Williamson SC; Wilson L; Lako M; Armstrong L; Hayward SW; Franco OE; Cates JM; Fordham SE; Przyborski S; Carr-Wilkinson J; Robson CN; Heer R
Eur Urol; 2013 Nov; 64(5):753-61. PubMed ID: 23582880
[TBL] [Abstract][Full Text] [Related]
18. Modeling Leukemia Stem Cells with Patient-Derived Induced Pluripotent Stem Cells.
Deslauriers AG; Kotini AG; Papapetrou EP
Methods Mol Biol; 2021; 2185():411-422. PubMed ID: 33165864
[TBL] [Abstract][Full Text] [Related]
19. Application of induced pluripotent stem cell technology for the investigation of hematological disorders.
Dolatshad H; Tatwavedi D; Ahmed D; Tegethoff JF; Boultwood J; Pellagatti A
Adv Biol Regul; 2019 Jan; 71():19-33. PubMed ID: 30341008
[TBL] [Abstract][Full Text] [Related]
20. Disease Modeling of Neurodegenerative Disorders Using Direct Neural Reprogramming.
Legault EM; Bouquety J; Drouin-Ouellet J
Cell Reprogram; 2022 Oct; 24(5):228-251. PubMed ID: 35749150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
